Showing posts with label meningococcal meningitis. Show all posts
Showing posts with label meningococcal meningitis. Show all posts

Tuesday, September 29, 2026

#WHO reports latest global #trends in #cholera, #meningitis and #plague (WHO, Sept. 29 '26)



29 September 2026 | News release 


    Cholera deaths increased by 30% in 2025, despite fewer cases being reported to the World Health Organization (WHO).  

    In 2025, 47 countries reported 451 499 cholera cases and 7870 deaths to WHO. This is the highest number of annual cholera deaths reported to WHO since 1999. These figures reflect surveillance data reported to WHO and not the actual global burden of cholera, which is estimated to be substantially higher as many cases go unreported.  

    Seven countries – Angola, Bangladesh, the Democratic Republic of the Congo, Nigeria, South Sudan, Sudan and Yemen – accounted for around 90% of all reported cholera cases and deaths globally. The WHO African Region reported the largest burden, with a 34% increase in cases and a 58% increase in deaths compared with 2024. 

    These findings are published in the latest edition of the Weekly Epidemiological Record alongside updates about two other epidemic-prone bacterial diseases: meningitis and plague.  

    "The rise in cholera deaths is a reminder of the challenge ahead,” said Dr Chikwe Ihekweazu, Executive Director of WHO's Health Emergencies Programme. 

    “No one should be dying from cholera today when we have the tools to prevent and treat this disease. The concentration of cases and deaths in a small number of countries shows where targeted investments in safe water, sanitation and hygiene could have the greatest impact. Combined with stronger disease surveillance, community engagement, vaccination and access to quality care, these investments can help turn this trend around." 

    Cholera is an acute diarrhoeal disease caused by Vibrio cholerae bacteria. The disease spreads through food and water contaminated with faeces, especially in areas without safe water and sanitation. 

    While cholera is preventable and treatable, it can be fatal if severe dehydration is not rapidly treated. More than one in five reported cholera deaths occurred outside health facilities, highlighting that too many patients are still not reaching care in time. Among patients treated in health facilities, the fatality rate was below 1% – a threshold for adequate care – globally. However, the rate exceeded 1% in 12 countries in 2025. 

    Global production of oral cholera vaccines more than doubled between 2022 and 2025, increasing from around 30 million to approximately 80 million doses annually, significantly improving vaccine availability. Last year, the International Coordinating Group (ICG) on Vaccine Provision approved 71 million doses for use in affected countries, including 20 million doses for preventive vaccination, which resumed earlier this year after being suspended for more than three years. 


Vaccination is advancing the fight to defeat meningitis by 2030  

    Bacterial meningitis continues to place a substantial burden on countries in the African meningitis belt, an area extending from Senegal to Ethiopia where epidemics occur regularly. In 2025, 24 of the 26 countries in the region reported 21 526 suspected cases and 971 deaths to WHO, corresponding to a fatality rate of 4.5%. Among countries reporting data for both years, cases declined by 5.9% compared with the previous year.  

    Meningitis is the inflammation of the tissues surrounding the brain and spinal cord, with bacterial meningitis being the most serious type. Four types of bacteria account for most cases of bacterial meningitis worldwide. 

    Vaccination has transformed the efforts to combat meningococcal meningitis, one of the main causes of bacterial meningitis. Since the introduction of the meningococcal A conjugate vaccine in 2010, cases of serogroup A have declined by more than 99% among vaccinated populations, and no confirmed case has been reported since 2017 in countries that introduced the vaccine. 

    A vaccine offering broader protection against five meningococcal serogroups, Men5CV/MMCV, is now being introduced in the region for both outbreak response through the ICG and preventive vaccination campaigns. In 2025, Niger became the first country to carry out a country-wide campaign using this vaccine.  


Surveillance remains essential to control plague 

    Plague is a bacterial disease that usually spreads between animals through fleas and can sometimes infect people. 

    Between 2019 and 2025, 10 countries reported suspected human plague cases to WHO, six of which reported confirmed cases. Overall, 3847 suspected cases and 423 deaths were reported to WHO, corresponding to a case fatality rate of 11%. Most cases were reported from the Democratic Republic of the Congo and Madagascar, where plague remains endemic in some areas. Plague may also occur in countries that do not report cases, and annual case numbers fluctuated depending on the timing, location and magnitude of outbreaks. 

    Continued surveillance of rodent and other animal populations, together with rapid response to outbreaks, remains essential to detect plague early, reduce transmission and prevent larger outbreaks.  


About WHO 

    Dedicated to the well-being of all people and guided by science, WHO leads and champions global efforts to give everyone, everywhere, an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people in more than 150 locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to support all countries to promote, provide and protect health. “Together for health. Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide.


Source: 


Link: https://www.who.int/news/item/29-09-2026-who-reports-latest-global-trends-in-cholera--meningitis-and-plague

____

Tuesday, September 22, 2026

Emergence of short-lived #meningococci causing focal #epidemics can be associated with #gene #transfer from carriage-associated #Neisseria

 


Abstract

In March 2026, an unusually large outbreak of invasive meningococcal disease (IMD) in Kent, UK, was linked to attendance at one nightclub over a single weekend. The outbreak organism was a Neisseria meningitidis variant belonging to the longstanding hyperinvasive genotype, cc41/44. Using genome analysis of six isolates from patients, alongside >48,000 meningococcal genomes, we investigated whether the outbreak variant had acquired traits potentially contributing to the highly invasive phenotype. The six isolates were capsular group B, sequence type (ST-)485, and essentially indistinguishable, consistent with the focal nature of the outbreak. Compared with their closest available relatives, we found changes mediated by phase variation, nucleotide variation, and horizontal gene transfer (HGT) involving adhesins, iron-acquisition systems (including Transferrin and Lactoferrin binding proteins, and FetA), and Type IV pili (Tfp), factors which affect bacteria-bacteria and bacteria-host interactions. These changes occurred in a ST-485 sub-lineage that expressed capsule at high levels and a PorA porin with a truncated surface-exposed epitope, both of which are predicted to reduce immune recognition. Donors for the HGT events were predominantly carriage-associated N. meningitidis and Neisseria cinerea. We show that meningococcal variants responsible for previous focal outbreaks have not been seen subsequently. We propose that focal outbreaks of IMD are caused by meningococcal variants that may have acquired traits from non- or less invasive organisms, but subsequently these variants disappear, as their highly invasive phenotype is inconsistent with sustained transmission. Ongoing disease surveillance alongside carriage studies are therefore essential to inform public health risk and manage epidemic IMD.


Competing Interest Statement

CMT and RME are inventors on patents for meningococcal vaccines. JPD is a co-founder and Director of Immunosig Ltd, a company which offers antigen microarray-based services. JL, RB, SAC and XB perform contract research on behalf of UKHSA for GSK, Pfizer, Sanofi and Serum Institute of India.


Funder Information Declared

Wellcome Trust, https://ror.org/029chgv08, 218205/Z/19/Z, 221924/Z/20/Z

NIH Common Fund, https://ror.org/001d55x84, R01AI127793

Source: 


Link: https://doi.org/10.64898/2026.09.17.752363

____

Wednesday, March 18, 2026

#UK, Northern Ireland: PHA #statement - #meningitis (March 18 '26)

 


The Public Health Agency (PHA) is aware of a probable case of Bacterial Meningitis in a pupil who attends a secondary school in Belfast. 

All appropriate public health actions have been completed.

As a precaution, PHA has worked closely with the school and has issued information to parents and guardians. 

Relevant guidance has also been shared with GP Out-of-Hours services and Emergency Departments.  

All individuals identified as close contacts have been risk assessed and where appropriate, have received antibiotic prophylaxis. 

We urge students, staff and families to remain vigilant for the signs and symptoms of meningitis and act fast if they suspect they may have it.

Symptoms of meningitis develop suddenly and can include: 

- a high temperature (fever) over 37.5C (99.5F)

- being sick

- a headache

- a blotchy rash that doesn't fade when a glass is rolled over it (this won't always develop)

- a stiff neck

- a dislike of bright lights

- drowsiness or unresponsiveness

- seizures (fits) 

PHA will continue to monitor the situation and provide any further advice as required. 

PHA is aware of the meningitis incident in Kent and is participating in regular UK wide meetings in relation to this. To date there is no evidence of spread beyond the South East of England.

For more information, visit: Update on meningitis incident in Kent England | HSC Public Health Agency

Further information on meningitis can be found at www.pha.site/meningitis-nidirect 

Source: 


Link: https://www.publichealth.hscni.net/news/pha-statement-meningitis

____

My New Space

Most Popular Posts